| ID Source | ID |
|---|---|
| PubMed CID | 10374840 |
| CHEMBL ID | 13823 |
| SCHEMBL ID | 1184744 |
| MeSH ID | M0479701 |
| Synonym |
|---|
| n-(3-chloro-phenyl)-guanidine |
| 1n-amino(immino)methyl-3-chloroaniline |
| bdbm50053608 |
| 2-(3-chlorophenyl)guanidine |
| CHEMBL13823 , |
| n-(3-chlorophenyl)guanidine |
| FT-0651363 |
| F2158-0392 |
| AKOS005208041 |
| 1-(3-chlorophenyl)guanidine |
| 6145-41-1 |
| 3-chlorophenylguanidine |
| AB43838 |
| AM81015 |
| DWLMIHRZURMFAQ-UHFFFAOYSA-N |
| SCHEMBL1184744 |
| DTXSID20438841 |
| VU0490376-1 |
| mfcd08236718 |
| ZB1102 |
| m-chlorophenylguanidine |
| Z979503082 |
| A857618 |
| EN300-238035 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | Ki | 0.0338 | 0.0010 | 0.8835 | 9.9000 | AID6335; AID6338; AID6339; AID6343 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 (µMol) | 60.5000 | 0.4000 | 3.1000 | 9.7000 | AID1463535 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 (µMol) | 13.7000 | 0.2100 | 5.5537 | 10.0000 | AID1463534 |
| Solute carrier family 22 member 3 | Homo sapiens (human) | IC50 (µMol) | 7.6000 | 0.0900 | 3.7277 | 9.5000 | AID1463536 |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | Ki | 0.0338 | 0.0010 | 0.8711 | 9.9000 | AID6335; AID6338; AID6339; AID6343 |
| Plasminogen | Homo sapiens (human) | Ki | 10,000.0000 | 0.0170 | 1.1560 | 4.4000 | AID157989 |
| Urokinase-type plasminogen activator | Homo sapiens (human) | Ki | 61.7297 | 0.0170 | 2.6268 | 7.0000 | AID215841; AID215976 |
| Cationic trypsin | Bos taurus (cattle) | Ki | 1,099.5050 | 0.0000 | 1.0753 | 9.0000 | AID215213; AID215237 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 0.0350 | 0.0001 | 0.8363 | 10.0000 | AID6335 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 0.0335 | 0.0000 | 0.7411 | 9.9000 | AID6335; AID6338; AID6339; AID6343; AID775163 |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | Ki | 0.0338 | 0.0010 | 0.8835 | 9.9000 | AID6335; AID6338; AID6339; AID6343 |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | Ki | 0.0338 | 0.0010 | 0.8835 | 9.9000 | AID6335; AID6338; AID6339; AID6343 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID6343 | Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors. |
| AID215976 | log1/Ki value was calculated against Urokinase-type plasminogen activator | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
| AID167329 | Minimal effective dose for its 5-HT3 -Stimulant potency in rabbit bladder preparation. | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors. |
| AID1463534 | Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of substrate [3H]MPP+ after 1 min by liquid scintillation counting method | 2017 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18 | A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3). |
| AID210572 | Inhibition against Tissue plasminogen activator at 1 mM | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
| AID775163 | Displacement of [3H]GR65630 from 5-HT3 receptor (unknown origin) expressed in mouse/rat NG108-15 cells after 30 mins by by liquid scintillation counting analysis | 2013 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21 | 2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character. |
| AID210841 | Inhibition against human plasma thrombin at 1.0 mM | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
| AID1463536 | Inhibition of human OCT3 expressed in HEK293 cells assessed as decrease in uptake of substrate [3H]MPP+ after 1 min by liquid scintillation counting method | 2017 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18 | A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3). |
| AID6332 | Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Electrostatic potential surfaces of 5-HT(3)R agonists suggest accessory cation-pi site adjacent to agonist binding domain. |
| AID1463539 | Selectivity ratio of IC50 for human OCT1 expressed in HEK293 cells to IC50 for human OCT3 expressed in HEK293 cells | 2017 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18 | A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3). |
| AID215237 | log1/Ki value was calculated against Trypsin | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
| AID157989 | Inhibition against human plasmin was determined at 0.5 mM | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
| AID215213 | Inhibition against Trypsin | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
| AID6335 | Binding affinity towards 5-hydroxytryptamine 3 receptor | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Electrostatic potential surfaces of 5-HT(3)R agonists suggest accessory cation-pi site adjacent to agonist binding domain. |
| AID6324 | Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Electrostatic potential surfaces of 5-HT(3)R agonists suggest accessory cation-pi site adjacent to agonist binding domain. |
| AID189728 | Compound tested for its 5-HT3 -Stimulant potency in rat relative to compound 6 ( Value = 1); Range 0.5-1.3 | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors. |
| AID95039 | Inhibition against human plasma Kallikrein at 2 mM | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
| AID1463535 | Inhibition of human OCT2 expressed in HEK293 cells assessed as decrease in uptake of substrate [3H]MPP+ after 1 min by liquid scintillation counting method | 2017 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18 | A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3). |
| AID1463537 | Selectivity ratio of IC50 for human OCT2 expressed in HEK293 cells to IC50 for human OCT3 expressed in HEK293 cells | 2017 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18 | A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3). |
| AID19834 | Partition coefficient in an aqueous 1-octanol buffer system by the shake-flask method | 2003 | Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6 | Conformationally-restricted analogues and partition coefficients of the 5-HT3 serotonin receptor ligands meta-chlorophenylbiguanide (mCPBG) and meta-chlorophenylguanidine (mCPG). |
| AID6338 | Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630 | 2003 | Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6 | Conformationally-restricted analogues and partition coefficients of the 5-HT3 serotonin receptor ligands meta-chlorophenylbiguanide (mCPBG) and meta-chlorophenylguanidine (mCPG). |
| AID215841 | Inhibition against Urokinase-type plasminogen activator | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
| AID6339 | Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand. | 2001 | Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12 | The binding of arylguanidines at 5-HT(3) serotonin receptors: a structure-affinity investigation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||